Press Room

Event

AAPS 2019

Start
Sunday, November 03, 2019 - 09:00
End
Wednesday, November 06, 2019 - 09:00
Location: Texas, United States
Booth Number: 447
Spray Drying Development by Design | Hovione

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Adam Neunuebel will be pleased to meet you.

adam-neunuebel-photo

Adam Neunuebel

Head of Business Development

 

HOVIONE POSTERS

Poster Name / Presentation Poster Number Presenter Presentation
Date / Time
Production of Lysozyme-PLGA Particles for Extended
Release Using Hot Melt Extrusion Technology		 M1230-02-09 João Henriques Nov 4
12.30 pm - 1.30 pm
A Fundamental Study on Strain Rate Sensitivity of
Spray Dried Solid Dispersions		 M1330-04-23 João Henriques Nov 4
1.30 pm - 2.30 pm
Statistical Approach on the Key Parameters of a
Dosator-Based Capsule Filling Process of
Carrier-Based and Spray-Dried Powders –
Impact on the In-Vitro Aerodynamic Performance		 M1430-08-50 Eunice Costa Nov 4
2.30 pm - 3.30 pm
Leveraging Amorphous Solid Dispersion Development
in an Integrated API to Tablet Pipeline		 T1130-04-24 João Henriques Nov 5
11.30 am - 12.30 am
Exploring the Physical Stability of Amorphous Drugs
The Thermodynamic Toolbox		 T1130-06-42 Maria Paisana Nov 5
11.30 am - 12.30 am
A Novel Laser Diffraction Methodology for the
Characterization
of ASD Speciation Events - An Itraconazole:
HPMC AS Case Study		 M1230-03-17 Maria Paisana Nov 5
2.30 pm - 3.30 pm
Performance Evaluation of ASD-Based Tablets:
Can Colloid Formation be Modelled?		 W0930-06-41 João Henriques Nov 6
9.30 am - 10.30 am
Comparative Evaluation of Pharmaceutical Powders
Flow Using Different Analytical Methodologies		 W0930-06-42 Maria Paisana Nov 6
9.30 am - 10.30 am
Powerful Combination between AQbD
and High-Throughput Analytical Toolkit
to Support an Efficient RP-LC Method Development		 W1130-06-41 Maria Paisana Nov 6
11.30 am - 12.30 am

 

You might be also interested in

 

 

Also in the Press Room

See All

Hovione is a global contract development and manufacturing organization (CDMO) company founded in Portugal in 1959. With approximately 2,400 team members worldwide, the company provides comprehensive services for drug substances, drug intermediates, and drug products in countries around the world. Japan in particular plays a very important role in Hovione's global strategy, and in 2017 it established a Japanese subsidiary in Osaka. The company plans to actively invest in further strengthening its organization and recruiting personnel. With development labs strategically located in Lisbon, Portugal, and New Jersey, USA, Hovione consistently provides superior solutions tailored to complex pharmaceutical challenges. Hovione is recognized globally for its scientific excellence, technological innovation, and customer-centric and integrated approach. Leveraging cutting-edge capabilities in chemical synthesis, particle engineering, and formulation development, the company supports its partners throughout the entire pharmaceutical life cycle.   Read the full article in Japanese Read the article translated in English   Visit the Yakuji Nippo online      

Press Clipping
Yakuji Nippo Magazine, 2 July 2025

Solving Complex Pharmaceutical Challenges

Jul 10, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping
Pharmiweb.com, 25 June 2025

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025

CDMO Hovione and biotechnology company Firstgene Life Sciences (of Xlife Sciences) have collaborated to advance Hovione’s drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC). “We are proud to advance the development of innovative oncology treatments that address a critical unmet need for precision gene expression at the tissue level,” said Hovione CEO Dr Jean-Luc Herbeaux. The virus-like particle technology will be engineered and functionalised for the specific carcinoma cell type using therapeutically validated AAVs, including a novel primer compound. Hovione will be responsible for molecular engineering, the supply of tailor-made virus-like particles and the execution of proof-of-concept studies. “HCC, the most common liver cancer and a leading cause of cancer-related death, continues to represent a major unmet medical need,” said Firstgene managing director Dr Alexander Zink. “The combination of Hovione’s expertise in complex chemistry and particle engineering and the commercialisation expertise of Xlife Sciences positions Firstgene well to offer patients potential new safe and effective therapy options.”   Read the full article at scientistlive.com    

Press Clipping
Scientist Live, 12 May 2025

Partnership advances liver cancer treatment

May 12, 2025

Also in Events

See All